220 related articles for article (PubMed ID: 29471417)
1. A study of circulating microRNAs identifies a new potential biomarker panel to distinguish aggressive prostate cancer.
Farran B; Dyson G; Craig D; Dombkowski A; Beebe-Dimmer JL; Powell IJ; Podgorski I; Heilbrun L; Bolton S; Bock CH
Carcinogenesis; 2018 Apr; 39(4):556-561. PubMed ID: 29471417
[TBL] [Abstract][Full Text] [Related]
2. Circulating microRNAs in plasma before and after radical prostatectomy.
McDonald AC; Raman JD; Shen J; Liao J; Pandya B; Vira MA
Urol Oncol; 2019 Nov; 37(11):814.e1-814.e7. PubMed ID: 31421994
[TBL] [Abstract][Full Text] [Related]
3. Circulating microRNAs in plasma among men with low-grade and high-grade prostate cancer at prostate biopsy.
McDonald AC; Vira M; Walter V; Shen J; Raman JD; Sanda MG; Patil D; Taioli E
Prostate; 2019 Jun; 79(9):961-968. PubMed ID: 30958910
[TBL] [Abstract][Full Text] [Related]
4. Circulating miRNAs as non-invasive biomarkers to predict aggressive prostate cancer after radical prostatectomy.
Hoey C; Ahmed M; Fotouhi Ghiam A; Vesprini D; Huang X; Commisso K; Commisso A; Ray J; Fokas E; Loblaw DA; He HH; Liu SK
J Transl Med; 2019 May; 17(1):173. PubMed ID: 31122242
[TBL] [Abstract][Full Text] [Related]
5. Circulating microRNA signature for the diagnosis of very high-risk prostate cancer.
Alhasan AH; Scott AW; Wu JJ; Feng G; Meeks JJ; Thaxton CS; Mirkin CA
Proc Natl Acad Sci U S A; 2016 Sep; 113(38):10655-60. PubMed ID: 27601638
[TBL] [Abstract][Full Text] [Related]
6. Plasma microRNAs as potential new biomarkers for early detection of early gastric cancer.
Zhu XL; Ren LF; Wang HP; Bai ZT; Zhang L; Meng WB; Zhu KX; Ding FH; Miao L; Yan J; Wang YP; Liu YQ; Zhou WC; Li X
World J Gastroenterol; 2019 Apr; 25(13):1580-1591. PubMed ID: 30983818
[TBL] [Abstract][Full Text] [Related]
7. Detection of circulating miRNAs: comparative analysis of extracellular vesicle-incorporated miRNAs and cell-free miRNAs in whole plasma of prostate cancer patients.
Endzeliņš E; Berger A; Melne V; Bajo-Santos C; Soboļevska K; Ābols A; Rodriguez M; Šantare D; Rudņickiha A; Lietuvietis V; Llorente A; Linē A
BMC Cancer; 2017 Nov; 17(1):730. PubMed ID: 29121858
[TBL] [Abstract][Full Text] [Related]
8. miRNAs as novel biomarkers in the management of prostate cancer.
Filella X; Foj L
Clin Chem Lab Med; 2017 May; 55(5):715-736. PubMed ID: 26751899
[TBL] [Abstract][Full Text] [Related]
9. Expression differences of circulating microRNAs in metastatic castration resistant prostate cancer and low-risk, localized prostate cancer.
Nguyen HC; Xie W; Yang M; Hsieh CL; Drouin S; Lee GS; Kantoff PW
Prostate; 2013 Mar; 73(4):346-54. PubMed ID: 22887127
[TBL] [Abstract][Full Text] [Related]
10. Recent scenario of microRNA as diagnostic and prognostic biomarkers of prostate cancer.
Shukla KK; Misra S; Pareek P; Mishra V; Singhal B; Sharma P
Urol Oncol; 2017 Mar; 35(3):92-101. PubMed ID: 27890424
[TBL] [Abstract][Full Text] [Related]
11. Discovery of circulating microRNAs associated with human prostate cancer using a mouse model of disease.
Selth LA; Townley S; Gillis JL; Ochnik AM; Murti K; Macfarlane RJ; Chi KN; Marshall VR; Tilley WD; Butler LM
Int J Cancer; 2012 Aug; 131(3):652-61. PubMed ID: 22052531
[TBL] [Abstract][Full Text] [Related]
12. Assessment of Serum microRNA Biomarkers to Predict Reclassification of Prostate Cancer in Patients on Active Surveillance.
Liu RSC; Olkhov-Mitsel E; Jeyapala R; Zhao F; Commisso K; Klotz L; Loblaw A; Liu SK; Vesprini D; Fleshner NE; Bapat B
J Urol; 2018 Jun; 199(6):1475-1481. PubMed ID: 29246734
[TBL] [Abstract][Full Text] [Related]
13. Circulating microRNAs and treatment response in the Phase II SWOG S0925 study for patients with new metastatic hormone-sensitive prostate cancer.
Cheng HH; Plets M; Li H; Higano CS; Tangen CM; Agarwal N; Vogelzang NJ; Hussain M; Thompson IM; Tewari M; Yu EY
Prostate; 2018 Feb; 78(2):121-127. PubMed ID: 29105802
[TBL] [Abstract][Full Text] [Related]
14. Circulating miR-20a and miR-26a as Biomarkers in Prostate Cancer.
Mohammadi Torbati P; Asadi F; Fard-Esfahani P
Asian Pac J Cancer Prev; 2019 May; 20(5):1453-1456. PubMed ID: 31127907
[TBL] [Abstract][Full Text] [Related]
15. Functional roles and potential clinical application of miRNA-345-5p in prostate cancer.
Tinay I; Tan M; Gui B; Werner L; Kibel AS; Jia L
Prostate; 2018 Sep; 78(12):927-937. PubMed ID: 29748958
[TBL] [Abstract][Full Text] [Related]
16. Implications of microRNA dysregulation in the development of prostate cancer.
Massillo C; Dalton GN; Farré PL; De Luca P; De Siervi A
Reproduction; 2017 Oct; 154(4):R81-R97. PubMed ID: 28878093
[TBL] [Abstract][Full Text] [Related]
17. Circulating microRNAs as potential new biomarkers for prostate cancer.
Sita-Lumsden A; Dart DA; Waxman J; Bevan CL
Br J Cancer; 2013 May; 108(10):1925-30. PubMed ID: 23632485
[TBL] [Abstract][Full Text] [Related]
18. Circulating microRNAs in plasma as potential biomarkers for the early detection of prostate cancer.
McDonald AC; Vira M; Shen J; Sanda M; Raman JD; Liao J; Patil D; Taioli E
Prostate; 2018 May; 78(6):411-418. PubMed ID: 29383739
[TBL] [Abstract][Full Text] [Related]
19. Combination of three miRNA (miR-141, miR-21, and miR-375) as potential diagnostic tool for prostate cancer recognition.
Porzycki P; Ciszkowicz E; Semik M; Tyrka M
Int Urol Nephrol; 2018 Sep; 50(9):1619-1626. PubMed ID: 30014459
[TBL] [Abstract][Full Text] [Related]
20. Plasma miRNAs as biomarkers to identify patients with castration-resistant metastatic prostate cancer.
Watahiki A; Macfarlane RJ; Gleave ME; Crea F; Wang Y; Helgason CD; Chi KN
Int J Mol Sci; 2013 Apr; 14(4):7757-70. PubMed ID: 23574937
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
